Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for treatment of psoriatic arthritis (PsA). We evaluated patient-reported outcomes (PROs) in patients with PsA refractory to ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR) and tumour necrosis factor inhibitor-naïv...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:RMD Open
Glavni autori: Strand, Vibeke, de Vlam, Kurt, Covarrubias-Cobos, Jose A, Mease, Philip J, Gladman, Dafna D, Graham, Daniela, Wang, Cunshan, Cappelleri, Joseph C, Hendrikx, Thijs, Hsu, Ming-Ann
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2019
Teme:
Psoriatic Arthritis
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6340575/
https://ncbi.nlm.nih.gov/pubmed/30713721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2018-000806
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items